Bellerophon Announces Top-Line Data from Phase 3 REBUILD Cli

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile... | June 5, 2023

Related Keywords

Canada , Peter Fernandes , Brian Ritchie , Bellerophon Therapeutics Inc , Exchange Commission , Globenewswire Inc , Nasdaq , Interstitial Lung Disease , Walk Distance , Respiratory Questionnaire , Clinical Worsening , Clinical Deterioration , Clinical Improvement , Chief Executive , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Bellerophon Therapeutics , Nc Stock Exchange , News , Information , Press Release , Trial , Kid , Lot , Feet , Its , Primary , Ndpoint , Elated , O , The , Change , N , Moderate , Rigorous , Physical , Activity , Gas , Safe , End , Consistent , Ith , Verall , Afety Blph Us0787713009 ,